Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX-HAIC with Bevacizumab or Cetuximab for Unresectable CRLM
NCT06988852Phase 2Recruiting
- Sponsor
- Tongji Hospital
- Start
- May 2023
- Primary completion
- Dec 2030
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, cetuximab, oxaliplatin, fluorouracil and folinic acid in colorectal cancer with liver metastasis (CRLM), sponsored by Tongji Hospital. Primary endpoint: Conversion to Resection Rate at 180 days. Started May 2023; status: recruiting.
02
Drugs
bevacizumabcetuximaboxaliplatinfluorouracilfolinic acid
03
Conditions
colorectal cancer with liver metastasis (CRLM)
Beyond the preview
Go deeper on NCT06988852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06988852.